Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Erythropoietin Abrogates Post-ischemic Activation of the NLRP3, NLRC4, and AIM2 Inflammasomes in Microglia/Macrophages in a TAK1-Dependent Manner.
Heinisch O, Zeyen T, Goldmann T, Prinz M, Huber M, Jung J, Arik E, Habib S, Slowik A, Reich A, Schulz JB, Habib P. Heinisch O, et al. Among authors: zeyen t. Transl Stroke Res. 2022 Oct;13(5):860. doi: 10.1007/s12975-021-00959-5. Transl Stroke Res. 2022. PMID: 34741750 Free PMC article. No abstract available.
Correction to: Erythropoietin Abrogates Post-Ischemic Activation of the NLRP3, NLRC4, and AIM2 Inflammasomes in Microglia/Macrophages in a TAK1-Dependent Manner.
Heinisch O, Zeyen T, Goldmann T, Prinz M, Huber M, Jung J, Arik E, Habib S, Slowik A, Reich A, Schulz JB, Habib P. Heinisch O, et al. Among authors: zeyen t. Transl Stroke Res. 2024 Jun;15(3):689-690. doi: 10.1007/s12975-023-01156-2. Transl Stroke Res. 2024. PMID: 37344721 Free PMC article. No abstract available.
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Zeyen T, Potthoff AL, Nemeth R, Heiland DH, Burger MC, Steinbach JP, Hau P, Tabatabai G, Glas M, Schlegel U, Grauer O, Krex D, Schnell O, Goldbrunner R, Sabel M, Thon N, Delev D, Clusmann H, Seidel C, Güresir E, Schmid M, Schuss P, Giordano FA, Radbruch A, Becker A, Weller J, Schaub C, Vatter H, Schilling J, Winkler F, Herrlinger U, Schneider M. Zeyen T, et al. Trials. 2022 Jan 19;23(1):57. doi: 10.1186/s13063-021-05977-0. Trials. 2022. PMID: 35045869 Free PMC article. Clinical Trial.
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Weller J, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel U, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Pietsch T, Tzaridis T, Zeyen T, Borger V, Güresir E, Vatter H, Herrlinger U, Schneider M. Weller J, et al. Among authors: zeyen t. J Neurooncol. 2022 Aug;159(1):95-101. doi: 10.1007/s11060-022-04046-z. Epub 2022 Jun 15. J Neurooncol. 2022. PMID: 35704157 Free PMC article. Clinical Trial.
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, Zeyen T, Schaub C, Müller W, Sperk E, Schmeel LC, Sahm K, Oster C, Kebir S, Hambsch P, Pietsch T, Bisdas S, Platten M, Glas M, Seidel C, Herrlinger U, Hölzel M. Giordano FA, et al. Among authors: zeyen t. Nat Commun. 2024 May 28;15(1):4210. doi: 10.1038/s41467-024-48416-9. Nat Commun. 2024. PMID: 38806504 Free PMC article. Clinical Trial.
135 results